<DOC>
	<DOCNO>NCT01838577</DOCNO>
	<brief_summary>The investigator wish document distribution EGFR somatic mutation , ass relationship specific genotype , clinical demographic , therapy , survival , large cohort EGFR mutant NSCLC . The investigator also wish comprehensively investigate relationship germline DNA risk EGFR mutant NSCLC developing , GWAS ( Genome-Wide Association Studies ) candidate gene approach , explore relationship germline DNA clinical outcome , order potentially identify germline genetic modifier EGFR TKI ( Tyrosine Kinase Inhibitor ) outcome .</brief_summary>
	<brief_title>Genetics EGFR ( Epidermal Growth Factor Receptor ) Mutation Study</brief_title>
	<detailed_description>Objective 1 : To identify germline allelic DNA variation associate somatic EGFR mutation NSCLC , Objective 2 : Correlation germline allelic variant survival EGFR somatic mutant NSCLC . Objective 3 : Study germline allelic DNA variation associate never /ex light smoke NSCLC . Objective 4 : Catalogue distribution somatic EGFR mutant genotypes 1,000 EGFR mutant NSCLC case describe relationship clinical outcome .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically diagnose NSCLC , histologies acceptable . Patients include study disease stage time disease course . Any type ( surgery , RadioTherapy , chemotherapy , target agent ) previous treatment line treatment eligible . Age â‰¥18 year . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol ; condition discuss patient registration trial . Before patient registration , write informed consent must give accord ICH/GCP ( International Conference Harmonisation/Good Clinical Practice ) , national/local regulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>